PACIFIC EDGE LIMITED — Capital/Financing Update 2026

May 24, 2026

25 May 2026

PacificEdge

CANCER DIAGNOSTICS

RETAIL OFFER TO CLOSE 28 MAY 2026; LIKELY TO BE SCALED

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX/ASX: PEB) today reminds shareholders that the retail offer to eligible existing shareholders to raise up to NZ$6 million (with the ability to accept over-subscriptions at PEB’s discretion) closes at 5.00pm NZT on Thursday, 28 May 2026 (Retail Offer).

The Retail Offer is open to “Eligible Shareholders”, who are all persons recorded on Pacific Edge’s share register at 7:00pm NZST on Friday, 8 May 2026 as being a holder of Pacific Edge shares and having an address in New Zealand. Eligible Shareholders can subscribe for up to NZ$50,000 of new shares under the Retail Offer.

As at 8am on 25 May 2026, PEB has received applications for $14.0 million under the Retail Offer.

While any decision as to the acceptance of oversubscriptions will not be made until after the Retail Offer has closed, based on the level of acceptances received to date, the Board considers it likely that scaling of applications will be required.

If applications are scaled, Pacific Edge will scale back the number of new shares to be allotted under the Retail Offer to each applicant by reference to the number of shares held by Eligible Shareholders accepting the Retail Offer at 7.00pm NZST on the record date of 8 May 2026.

Further scaling of applications received from Eligible Shareholders who participated in Pacific Edge’s previous retail offer in August 2025 may also be required, given NZX Listing Rules applicable to the 2025 and 2026 retail offers limit the amount that each shareholder can participate in retail offers within 12 months of each other to NZ$50,000 in aggregate.

Pacific Edge intends to use its placement capacity under the NZX Listing Rules to minimise such further scaling, but there is a risk that Pacific Edge has insufficient remaining placement capacity to avoid further scaling in its entirety. If further scaling of such applications is required, it will also be undertaken by reference to the number of shares held by Eligible Shareholders accepting the Retail Offer at 7:00pm NZST on the record date of 8 May 2026.

More information about scaling can be found in the Retail Offer Document.

Eligible Shareholders are encouraged to read the Retail Offer Document and investor presentation relating to the capital raising which are available online at www.pacificedge.capitalraise.co.nz, and if in any doubt about whether or not to apply for new shares under the Retail Offer, to consult with their broker, or a financial or other professional adviser.

Eligible Shareholders who wish to participate in the Retail Offer should submit an online application no later than 5.00pm NZST on Thursday, 28 May 2026.

Eligible Shareholders who have completed an application do not need to take any further action.

---

Pacific Edge is grateful for the ongoing support of Pacific Edge shareholders and will release the results of the Retail Offer in the week commencing 1 June 2026.

Ends.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer

For more information:

Investors:
Dr Peter Meintjes
Chief Executive
Pacific Edge
P: 022 032 1263

Media:
Richard Inder
The Project
P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with hematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.

2